|
GB9818731D0
(en)
*
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Compounds
|
|
DE69930328T2
(de)
|
1998-08-27 |
2006-12-14 |
Spirogen Ltd., Ryde |
Dimere Pyrrolobenzodiazepine
|
|
GB9818732D0
(en)
*
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Collection of compounds
|
|
GB9818730D0
(en)
*
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Collections of compounds
|
|
FR2825705B1
(fr)
*
|
2001-06-08 |
2005-05-20 |
Aventis Pharma Sa |
Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
|
|
FR2835186B1
(fr)
|
2002-01-28 |
2006-10-20 |
Aventis Pharma Sa |
Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
|
|
FR2844273B1
(fr)
|
2002-09-05 |
2008-04-04 |
Aventis Pharma Sa |
Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
|
|
GB0226593D0
(en)
*
|
2002-11-14 |
2002-12-24 |
Consultants Ltd |
Compounds
|
|
EP1605847B1
(en)
*
|
2003-03-07 |
2009-09-16 |
Board Of Regents, The University Of Texas System |
Antibody-targeted photodynamic therapy
|
|
GB0321295D0
(en)
|
2003-09-11 |
2003-10-15 |
Spirogen Ltd |
Synthesis of protected pyrrolobenzodiazepines
|
|
SI2270010T1
(sl)
*
|
2004-03-01 |
2012-05-31 |
Spirogen Ltd |
hidroksi H pirolo c benzodiazepin onski derivati kot ključni intermediati za pripravo C substituiranih pirolobenzodiazepinov
|
|
GB0404577D0
(en)
*
|
2004-03-01 |
2004-04-07 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
|
GB0404574D0
(en)
*
|
2004-03-01 |
2004-04-07 |
Spirogen Ltd |
Amino acids
|
|
JP5166861B2
(ja)
*
|
2004-03-09 |
2013-03-21 |
スピロゲン リミティッド |
ピロロベンゾジアゼピン
|
|
FR2869231B1
(fr)
*
|
2004-04-27 |
2008-03-14 |
Sod Conseils Rech Applic |
Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
|
|
GB0410725D0
(en)
*
|
2004-05-13 |
2004-06-16 |
Spirogen Ltd |
Pyrrolobenzodiazepine therapeutic agents
|
|
AU2005252178B2
(en)
*
|
2004-06-02 |
2011-04-21 |
Eli Lilly And Company |
Histamine H3 receptor agents, preparation and therapeutic uses
|
|
WO2006070380A1
(en)
*
|
2004-12-27 |
2006-07-06 |
Council Of Scientific And Industrial Research |
Pyrrolo [2, 1-c] [1, 4] benzodiazepine-anthraquinone conjugates useful as antitumour agents
|
|
PL1879901T3
(pl)
|
2005-04-21 |
2010-06-30 |
Medimmune Ltd |
Pirolobenzodiazepiny
|
|
JO2768B1
(en)
*
|
2005-07-29 |
2014-03-15 |
تيبوتيك فارماسيوتيكالز ليمتد |
Large cyclic inhibitors of hepatitis C virus
|
|
US8637664B2
(en)
*
|
2005-10-05 |
2014-01-28 |
Spirogen Sarl |
Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
|
|
SI1813614T1
(sl)
|
2006-01-25 |
2012-01-31 |
Sanofi 174 |
Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
|
|
ES2673822T3
(es)
*
|
2006-07-18 |
2018-06-25 |
Sanofi |
Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
|
|
GB0619325D0
(en)
*
|
2006-09-30 |
2006-11-08 |
Univ Strathclyde |
New compounds
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
PL2019104T3
(pl)
|
2007-07-19 |
2014-03-31 |
Sanofi Sa |
Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne
|
|
WO2009016647A1
(en)
*
|
2007-08-01 |
2009-02-05 |
Council Of Scientific & Industrial Research |
Pyrrolo [2,1-c][1, 4] benzodiazepine-glycoside prodrugs useful as a selective anti tumor agent
|
|
GB0813432D0
(en)
|
2008-07-22 |
2008-08-27 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
|
GB0819095D0
(en)
|
2008-10-17 |
2008-11-26 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
|
CN102365021B
(zh)
|
2009-02-05 |
2015-07-15 |
伊缪诺金公司 |
新型苯并二氮杂*衍生物
|
|
AU2015224492B2
(en)
*
|
2009-02-05 |
2017-04-20 |
Immunogen, Inc. |
Novel benzodiazepine derivatives
|
|
FR2949469A1
(fr)
|
2009-08-25 |
2011-03-04 |
Sanofi Aventis |
Derives anticancereux, leur preparation et leur application en therapeutique
|
|
TW201116297A
(en)
|
2009-10-02 |
2011-05-16 |
Sanofi Aventis |
Antibodies that specifically bind to the EphA2 receptor
|
|
JP5187534B2
(ja)
*
|
2010-02-12 |
2013-04-24 |
有機合成薬品工業株式会社 |
Ｎ−ｔｅｒｔ−ブトキシカルボニル−４−ホルミルピペリジンの製造方法
|
|
MX391454B
(es)
|
2010-04-15 |
2025-03-05 |
Seagen Inc |
Compuesto de engarce-fármaco para conjugación a una unidad de ligando.
|
|
US8697688B2
(en)
|
2010-04-15 |
2014-04-15 |
Seattle Genetics Inc. |
Pyrrolobenzodiazepines used to treat proliferative diseases
|
|
GB201006340D0
(en)
|
2010-04-15 |
2010-06-02 |
Spirogen Ltd |
Synthesis method and intermediates
|
|
DK2528625T3
(da)
*
|
2010-04-15 |
2013-10-14 |
Spirogen Sarl |
Pyrrolobenzodiazepiner og konjugater deraf
|
|
FR2963007B1
(fr)
|
2010-07-26 |
2013-04-05 |
Sanofi Aventis |
Derives anticancereux, leur preparation et leur application therapeutique
|
|
US9540443B2
(en)
|
2011-01-26 |
2017-01-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies
|
|
JP6049642B2
(ja)
|
2011-02-15 |
2016-12-21 |
イミュノジェン・インコーポレーテッド |
複合体の調製方法
|
|
UA110640C2
(uk)
*
|
2011-05-05 |
2016-01-25 |
Янссен Фармацевтика Нв |
ПРОТИГРИБКОВІ 5,6-ДИГІДРО-4Н-ПІРОЛО[1,2-a][1,4]БЕНЗОДІАЗЕПІНИ ТА 6Н-ПІРОЛО[1,2-a][1,4]БЕНЗОДІАЗЕПІНИ, ЯКІ ЗАМІЩЕНІ ГЕТЕРОЦИКЛІЧНИМИ ПОХІДНИМИ
|
|
JP6170494B2
(ja)
|
2011-09-20 |
2017-07-26 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン
|
|
JP6104257B2
(ja)
*
|
2011-10-14 |
2017-03-29 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピンおよびそのコンジュゲート
|
|
ES2945932T3
(es)
|
2011-10-14 |
2023-07-10 |
Seagen Inc |
Pirrolobenzodiazepinas y conjugados dirigidos
|
|
CA2850096C
(en)
*
|
2011-10-14 |
2018-07-03 |
Spirogen Sarl |
Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
|
|
CA2850103C
(en)
|
2011-10-14 |
2019-09-10 |
Spirogen Sarl |
Pyrrolobenzodiazepines
|
|
CN103998449A
(zh)
|
2011-10-14 |
2014-08-20 |
斯皮罗根有限公司 |
吡咯并苯并二氮杂卓
|
|
WO2013055993A1
(en)
|
2011-10-14 |
2013-04-18 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
PE20190658A1
(es)
|
2012-02-24 |
2019-05-08 |
Abbvie Stemcentrx Llc |
Moduladores y metodos de empleo novedosos
|
|
CA2871172C
(en)
|
2012-04-30 |
2020-08-25 |
Spirogen Sarl |
Pyrrolobenzodiazepines
|
|
US9321774B2
(en)
|
2012-04-30 |
2016-04-26 |
Medimmune Limited |
Pyrrolobenzodiazepines
|
|
WO2013177481A1
(en)
|
2012-05-25 |
2013-11-28 |
Immunogen, Inc. |
Benzodiazepines and conjugates thereof
|
|
CN116574185A
(zh)
|
2012-07-25 |
2023-08-11 |
塞尔德克斯医疗公司 |
抗kit抗体及其用途
|
|
ES2649990T3
(es)
|
2012-10-12 |
2018-01-16 |
Medimmune Limited |
Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas
|
|
EP2906249B1
(en)
|
2012-10-12 |
2018-06-27 |
MedImmune Limited |
Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
|
|
EP2906250B1
(en)
|
2012-10-12 |
2018-05-30 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
|
CN104837502B
(zh)
|
2012-10-12 |
2018-08-10 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
|
US10695433B2
(en)
|
2012-10-12 |
2020-06-30 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US10751346B2
(en)
|
2012-10-12 |
2020-08-25 |
Medimmune Limited |
Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
|
|
AU2013328674B2
(en)
|
2012-10-12 |
2017-06-22 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
DK2906298T3
(en)
|
2012-10-12 |
2018-12-17 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
AU2013328625B2
(en)
|
2012-10-12 |
2016-12-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US10131682B2
(en)
|
2012-11-24 |
2018-11-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
|
|
CN105189507A
(zh)
|
2012-12-21 |
2015-12-23 |
斯皮罗根有限公司 |
吡咯并苯并二氮杂卓及其结合物
|
|
CN105246894A
(zh)
|
2012-12-21 |
2016-01-13 |
斯皮罗根有限公司 |
用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
|
|
SG11201507214SA
(en)
|
2013-03-13 |
2015-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
NZ710746A
(en)
|
2013-03-13 |
2018-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CA2905181C
(en)
|
2013-03-13 |
2020-06-02 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
|
|
AU2014244424A1
(en)
|
2013-03-14 |
2015-08-27 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
AU2014312310A1
(en)
|
2013-08-28 |
2016-04-07 |
Abbvie Stemcentrx Llc |
Novel SEZ6 modulators and methods of use
|
|
MX2016003256A
(es)
|
2013-09-12 |
2016-06-07 |
Halozyme Inc |
Anticuerpos modificados del receptor de factor de crecimiento anti-epidermico y metodos de uso de los mismos.
|
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EP3054985B1
(en)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP3054986B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EA201691214A1
(ru)
|
2013-12-13 |
2016-12-30 |
Дженентек, Инк. |
Антитела к cd33 и иммуноконъюгаты
|
|
CA2938919C
(en)
|
2014-02-28 |
2020-12-29 |
Hangzhou Dac Biotech Co., Ltd |
Charged linkers and their uses for conjugation
|
|
MX2016012830A
(es)
|
2014-04-11 |
2017-01-05 |
Medimmune Llc |
Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
|
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
|
WO2015179658A2
(en)
|
2014-05-22 |
2015-11-26 |
Genentech, Inc. |
Anti-gpc3 antibodies and immunoconjugates
|
|
JP6531166B2
(ja)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
|
JP6943760B2
(ja)
|
2014-09-12 |
2021-10-06 |
ジェネンテック， インコーポレイテッド |
抗ｂ７−ｈ４抗体及び免疫複合体
|
|
MX2017003123A
(es)
|
2014-09-12 |
2017-05-12 |
Genentech Inc |
Anticuerpos y conjugados modificados geneticamente con cisteina.
|
|
LT3191135T
(lt)
|
2014-09-12 |
2020-11-25 |
Genentech, Inc. |
Anti-her2 antikūnai ir imunokonjugatai
|
|
KR20170066421A
(ko)
|
2014-09-12 |
2017-06-14 |
제넨테크, 인크. |
항-cll-1 항체 및 면역접합체
|
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
HK1243629A1
(zh)
|
2014-09-17 |
2018-07-20 |
基因泰克公司 |
包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
|
|
JP6863888B2
(ja)
|
2014-10-01 |
2021-04-21 |
メディミューン，エルエルシー |
ポリペプチドをコンジュゲートさせる方法
|
|
AU2015352545B2
(en)
|
2014-11-25 |
2020-10-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
JP6676650B2
(ja)
|
2015-03-13 |
2020-04-08 |
エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． |
疾患を処置するためのコンジュゲート
|
|
WO2016164916A1
(en)
|
2015-04-10 |
2016-10-13 |
Thomas Jefferson University |
Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
CN112125929A
(zh)
|
2015-06-15 |
2020-12-25 |
杭州多禧生物科技有限公司 |
用于偶联的亲水链接体
|
|
FI3319936T3
(fi)
|
2015-07-12 |
2026-03-12 |
Hangzhou Dac Biotech Co Ltd |
Silloituslinkkereitä soluun sitoutuvien molekyylien konjugoimiseksi
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
SG10202106529XA
(en)
|
2015-07-21 |
2021-07-29 |
Immunogen Inc |
Methods of preparing cytotoxic benzodiazepine derivatives
|
|
CA2996902C
(en)
|
2015-10-02 |
2020-06-02 |
Genentech, Inc. |
Pyrrolobenzodiazepine antibody drug conjugates and methods of use
|
|
EP3362100B1
(en)
|
2015-10-16 |
2022-06-22 |
Genentech, Inc. |
Hindered disulfide drug conjugates
|
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
|
CN108495653A
(zh)
|
2016-01-27 |
2018-09-04 |
免疫医疗有限责任公司 |
用于制备具有定义的糖基化模式抗体的方法
|
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
|
JP2019513371A
(ja)
|
2016-04-01 |
2019-05-30 |
アビディティー バイオサイエンシーズ エルエルシー |
核酸ポリペプチド組成物とその使用
|
|
TWI781098B
(zh)
|
2016-04-15 |
2022-10-21 |
美商宏觀基因股份有限公司 |
新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
|
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
TW201808336A
(zh)
|
2016-05-11 |
2018-03-16 |
賽諾菲公司 |
用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
|
|
EP3465221B1
(en)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
|
US11046776B2
(en)
|
2016-08-05 |
2021-06-29 |
Genentech, Inc. |
Multivalent and multiepitopic antibodies having agonistic activity and methods of use
|
|
WO2018031662A1
(en)
|
2016-08-11 |
2018-02-15 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
CA3042442C
(en)
|
2016-11-14 |
2024-01-02 |
Hangzhou Dac Biotech Co., Ltd |
Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses of such conjugates with the linkers
|
|
JP7313684B2
(ja)
|
2016-11-21 |
2023-07-25 |
キュレアブ ゲーエムベーハー |
抗ｇｐ７３抗体及びイムノコンジュゲート
|
|
MX375569B
(es)
|
2017-02-08 |
2025-03-04 |
Adc Therapeutics Sa |
Conjugados de pirrolobenzodiazepinas y anticuerpos
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
PT3612537T
(pt)
|
2017-04-18 |
2022-08-29 |
Medimmune Ltd |
Conjugados de pirrolobenzodiazepina
|
|
ES2977788T3
(es)
|
2017-04-20 |
2024-08-30 |
Adc Therapeutics Sa |
Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
|
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
|
MX2019015042A
(es)
|
2017-06-14 |
2020-08-06 |
Adc Therapeutics Sa |
Regimen de dosificacion.
|
|
AU2018308088B2
(en)
|
2017-07-25 |
2025-05-29 |
Truebinding, Inc. |
Treating cancer by blocking the interaction of TIM-3 and its ligand
|
|
DK3668874T3
(da)
|
2017-08-18 |
2022-02-14 |
Medimmune Ltd |
Pyrrolobenzodiazepin-konjugater
|
|
IL301637B2
(en)
|
2017-09-29 |
2024-10-01 |
Daiichi Sankyo Co Ltd |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
US12583932B2
(en)
|
2018-11-16 |
2026-03-24 |
Virtuoso Binco, Inc. |
CD38 and ICAM1 antibodies and uses thereof
|
|
IL312067B2
(en)
|
2018-12-21 |
2025-08-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and uses thereof
|
|
AU2020214796A1
(en)
|
2019-01-30 |
2021-07-29 |
Truebinding, Inc. |
Anti-Gal3 antibodies and uses thereof
|
|
KR102890251B1
(ko)
|
2019-03-15 |
2025-11-25 |
메드임뮨 리미티드 |
암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트
|
|
GB201908128D0
(en)
|
2019-06-07 |
2019-07-24 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP4684799A2
(en)
|
2019-12-06 |
2026-01-28 |
TrueBinding, Inc. |
Antibodies that disrupt the interaction of gal3 and insulin receptor or integrins and methods of use thereof
|
|
US11555190B2
(en)
|
2020-03-19 |
2023-01-17 |
Avidity Biosciences, Inc. |
Compositions and methods of treating Facioscapulohumeral muscular dystrophy
|
|
AU2021241682B2
(en)
|
2020-03-27 |
2026-02-12 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle dystrophy
|
|
WO2021242776A2
(en)
|
2020-05-26 |
2021-12-02 |
Truebinding, Inc. |
Methods of treating inflammatory diseases by blocking galectin-3
|
|
JP2024526764A
(ja)
|
2021-07-13 |
2024-07-19 |
トゥルーバインディング，インコーポレイテッド |
タンパク質凝集を防止する方法
|
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
|
MX2024003266A
(es)
|
2021-09-16 |
2024-04-03 |
Avidity Biosciences Inc |
Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|
|
CA3238590A1
(en)
|
2021-11-09 |
2023-05-19 |
Truebinding, Inc. |
Methods of treating or inhibiting cardiovascular diseases
|
|
CA3257258A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-Ly6E antibodies, immunoconjugates, and their uses
|